Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.53 |
| ▸ | CCND1 | P24385 | 16/20 | 0.53 |
| ▸ | CCND2 | P30279 | 14/20 | 0.53 |
| ▸ | CCND3 | P30281 | 14/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.53 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.52 |
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339799 | 0.92 | CDK4 (0.51) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3345115 | 0.85 | CDK4 (0.61) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3338824 | 0.85 | CDK4 (0.71) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3341049 | 0.85 | CDK4 (0.52) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3341382 | 0.83 | CDK4 (0.54) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3339257 | 0.81 | CDK4 (0.52) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3336784 | 0.80 | CDK4 (0.45) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3343867 | 0.79 | CDK4 (0.52) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3344302 | 0.79 | CDK4 (0.52) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL3339634 | 0.79 | CDK4 (0.66) | CDK4CCND1CCND2CCND3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | claimed |
| EP-2142543-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | CDK4 47/4885CCND1 141/4885CCND2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.